《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》解读

2021-06-25 临床药物治疗杂志.2021.19(6):41-45.

《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》（简称指南）是在2020 年版基础上，结合国内外最新研究进展和临床实践的需要，增加深静脉血栓的诊治、重要脏器功能的评估，对胸部X 线检查进行了重新定位，

中文标题：

发布机构：

发布日期：

2021-06-25

简要介绍：

《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》（简称指南）是在2020 年版基础上，结合国内外最新研究进展和临床实践的需要，增加深静脉血栓的诊治、重要脏器功能的评估，对胸部X 线检查进行了重新定位，更新了分子靶向和免疫检查点抑制剂相关检测和治疗的内容。对指南学习和理解有利于进一步规范和提高我国晚期肺癌的诊疗水平，因此对指南进行符合我国临床实践的解读。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=0f8df1c00212e758, title=《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》解读, enTitle=, guiderFrom=临床药物治疗杂志.2021.19(6):41-45., authorId=0, author=, summary=《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》（简称指南）是在2020 年版基础上，结合国内外最新研究进展和临床实践的需要，增加深静脉血栓的诊治、重要脏器功能的评估，对胸部X 线检查进行了重新定位，, cover=https://img.medsci.cn/2021715/1626282198472_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri Jun 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #333333;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》（简称指南）是在2020 年版基础上，结合国内外最新研究进展和临床实践的需要，增加深静脉血栓的诊治、重要脏器功能的评估，对胸部X 线检查进行了重新定位，更新了分子靶向和免疫检查点抑制剂相关检测和治疗的内容。对指南学习和理解有利于进一步规范和提高我国晚期肺癌的诊疗水平，因此对指南进行符合我国临床实践的解读。</p> </div> </div> </div>, tagList=[TagDto(tagId=3637, tagName=原发性肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3637, guiderKeyword=原发性肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8014, appHits=442, showAppHits=0, pcHits=807, showPcHits=7566, likes=1, shares=34, comments=14, approvalStatus=1, publishedTime=Thu Jul 15 01:51:49 CST 2021, publishedTimeString=2021-06-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 15 01:03:26 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:14:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_期原发性肺癌中国治疗指南_2021年版_解读_艾斌.pdf)])

_期原发性肺癌中国治疗指南_2021年版_解读_艾斌.pdf

下载请点击：

评论区 (11)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1222454, encodeId=0296122245406, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Wed May 25 21:48:34 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189938, encodeId=00c0118993877, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKe1k5dqfdltkTXNsqhZ6J3OibfZZ5TIxZaELGLiatrCExTVYVRxK2qstmUxRBor2E1dia87RsM9rH7Q/132, createdBy=f1665251509, createdName=Shirlyhong , createdTime=Thu Feb 03 16:46:11 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187029, encodeId=d42c118e02956, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66c6390820, createdName=ms9000001662354483, createdTime=Sat Jan 22 00:16:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186998, encodeId=f21d11869981d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:03:43 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183044, encodeId=0593118304433, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:16:40 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
2022-05-25 ms6980619036574494

谢谢分享

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1222454, encodeId=0296122245406, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Wed May 25 21:48:34 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189938, encodeId=00c0118993877, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKe1k5dqfdltkTXNsqhZ6J3OibfZZ5TIxZaELGLiatrCExTVYVRxK2qstmUxRBor2E1dia87RsM9rH7Q/132, createdBy=f1665251509, createdName=Shirlyhong , createdTime=Thu Feb 03 16:46:11 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187029, encodeId=d42c118e02956, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66c6390820, createdName=ms9000001662354483, createdTime=Sat Jan 22 00:16:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186998, encodeId=f21d11869981d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:03:43 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183044, encodeId=0593118304433, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:16:40 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
2022-02-03 Shirlyhong

谢谢分享

134 0
[GetPortalCommentsPageByObjectIdResponse(id=1222454, encodeId=0296122245406, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Wed May 25 21:48:34 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189938, encodeId=00c0118993877, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKe1k5dqfdltkTXNsqhZ6J3OibfZZ5TIxZaELGLiatrCExTVYVRxK2qstmUxRBor2E1dia87RsM9rH7Q/132, createdBy=f1665251509, createdName=Shirlyhong , createdTime=Thu Feb 03 16:46:11 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187029, encodeId=d42c118e02956, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66c6390820, createdName=ms9000001662354483, createdTime=Sat Jan 22 00:16:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186998, encodeId=f21d11869981d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:03:43 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183044, encodeId=0593118304433, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:16:40 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
2022-01-22 ms9000001662354483

学习

170 0
[GetPortalCommentsPageByObjectIdResponse(id=1222454, encodeId=0296122245406, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Wed May 25 21:48:34 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189938, encodeId=00c0118993877, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKe1k5dqfdltkTXNsqhZ6J3OibfZZ5TIxZaELGLiatrCExTVYVRxK2qstmUxRBor2E1dia87RsM9rH7Q/132, createdBy=f1665251509, createdName=Shirlyhong , createdTime=Thu Feb 03 16:46:11 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187029, encodeId=d42c118e02956, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66c6390820, createdName=ms9000001662354483, createdTime=Sat Jan 22 00:16:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186998, encodeId=f21d11869981d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:03:43 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183044, encodeId=0593118304433, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:16:40 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
2022-01-21 未来将来

学习

155 0
[GetPortalCommentsPageByObjectIdResponse(id=1222454, encodeId=0296122245406, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Wed May 25 21:48:34 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189938, encodeId=00c0118993877, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKe1k5dqfdltkTXNsqhZ6J3OibfZZ5TIxZaELGLiatrCExTVYVRxK2qstmUxRBor2E1dia87RsM9rH7Q/132, createdBy=f1665251509, createdName=Shirlyhong , createdTime=Thu Feb 03 16:46:11 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187029, encodeId=d42c118e02956, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66c6390820, createdName=ms9000001662354483, createdTime=Sat Jan 22 00:16:53 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186998, encodeId=f21d11869981d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:03:43 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183044, encodeId=0593118304433, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:16:40 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
2022-01-11 lexi Liao

感谢

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

《Ⅳ期原发性肺癌中国治疗指南（2021 年版）》解读

相关指南

拓展阅读

科室

工具

服务